Cardiol Therapeutics Inc.

TSX:CRDL Rapporto sulle azioni

Cap. di mercato: CA$184.4m

Cardiol Therapeutics Gestione

Gestione criteri di controllo 1/4

Cardiol Therapeutics Il CEO è David Elsley, nominato in Jan2017, e ha un mandato di 7.83 anni. la retribuzione annua totale è CA$ 748.10K, composta da 70.2% di stipendio e 29.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.51% delle azioni della società, per un valore di CA$ 2.78M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 2.8 anni.

Informazioni chiave

David Elsley

Amministratore delegato

CA$748.1k

Compenso totale

Percentuale dello stipendio del CEO70.2%
Mandato del CEO7.8yrs
Proprietà del CEO1.5%
Durata media del management3.9yrs
Durata media del Consiglio di amministrazione2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Elsley rispetto agli utili di Cardiol Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-CA$36m

Jun 30 2024n/an/a

-CA$29m

Mar 31 2024n/an/a

-CA$30m

Dec 31 2023CA$748kCA$525k

-CA$28m

Sep 30 2023n/an/a

-CA$28m

Jun 30 2023n/an/a

-CA$30m

Mar 31 2023n/an/a

-CA$29m

Dec 31 2022CA$654kCA$525k

-CA$31m

Sep 30 2022n/an/a

-CA$30m

Jun 30 2022n/an/a

-CA$32m

Mar 31 2022n/an/a

-CA$32m

Dec 31 2021CA$1mCA$455k

-CA$32m

Sep 30 2021n/an/a

-CA$35m

Jun 30 2021n/an/a

-CA$30m

Mar 31 2021n/an/a

-CA$27m

Dec 31 2020CA$517kCA$450k

-CA$21m

Sep 30 2020n/an/a

-CA$14m

Jun 30 2020n/an/a

-CA$13m

Mar 31 2020n/an/a

-CA$13m

Dec 31 2019CA$450kCA$450k

-CA$14m

Sep 30 2019n/an/a

-CA$20m

Jun 30 2019n/an/a

-CA$21m

Mar 31 2019n/an/a

-CA$19m

Dec 31 2018CA$713kCA$363k

-CA$16m

Compensazione vs Mercato: La retribuzione totale di David ($USD 535.22K ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 167.81K ).

Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

David Elsley

7.8yrs

Mandato

CA$748,100

Compensazione

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Elsley
President7.8yrsCA$748.10k1.51%
CA$ 2.8m
Christopher Waddick
CFO, Corporate Secretary & Director6.3yrsCA$294.80k0.14%
CA$ 253.9k
Bernard Lim
Chief Operating Officer3.9yrsCA$515.90k0.038%
CA$ 69.3k
Andrew Hamer
Chief Medical Officer & Head of Research & Development3.7yrsCA$746.56k0.56%
CA$ 1.0m
Trevor Burns
Investor Relationsno dataNessun datoNessun dato
John Geddes
Vice President of Corporate Developmentless than a yearNessun datoNessun dato

3.9yrs

Durata media

Gestione esperta: Il team dirigenziale di CRDL è considerato esperto (durata media dell'incarico 3.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Elsley
President7.8yrsCA$748.10k1.51%
CA$ 2.8m
Christopher Waddick
CFO, Corporate Secretary & Director2.5yrsCA$294.80k0.14%
CA$ 253.9k
Colin Stott
Independent Director4.9yrsCA$60.00k0.18%
CA$ 328.9k
Jennifer Chao
Independent Director2.7yrsCA$76.92k0.13%
CA$ 230.8k
Peter Pekos
Independent Director6.9yrsCA$58.00k0.58%
CA$ 1.1m
Michael Willner
Independent Director3.2yrsCA$71.52k1.07%
CA$ 2.0m
Paul Ridker
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato
Bruce McManus
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato
Teri Loxam
Independent Director2.5yrsCA$82.32k0.15%
CA$ 277.0k
Guillermo Torre-Amione
Independent Chairman6.3yrsCA$112.68k0.28%
CA$ 509.0k
Joseph Hill
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato

2.8yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CRDL non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.